Why must methotrexate continue in psoriatic arthritis even after the skin has cleared completely?

The most common methotrexate adherence error in the psoriatic arthritis clinic is the patient whose skin plaque clears on methotrexate — PASI drops from fourteen to two, the elbows and scalp look nearly normal — who then stops the medication reasoning the disease has resolved. This inference is mechanistically incorrect because psoriatic arthritis is not primarily a skin disease with incidental joint involvement; it is a systemic Th17-driven inflammatory disease in which skin and joint compartments are both targets of the same underlying immune dysregulation, but they respond to treatment at different rates and through partially dissociate pathways. Skin psoriasis is driven primarily by dermal Th17 cells secreting IL-17A and IL-22, which act directly on keratinocytes to promote hyperproliferation, acanthosis, parakeratosis, and the formation of the Munro microabscesses that define plaque psoriasis histologically. IL-22 is particularly important for the keratinocyte response — it activates STAT3 and promotes the anti-apoptotic signals that keep keratinocytes proliferating when they should differentiate. Psoriatic joint disease involves the same IL-17A and TNF-alpha signals, but joint synovitis is additionally driven by TNF-alpha from synovial macrophages and fibroblast-like synoviocytes, IL-23 from entheseal macrophages at the cartilage-tendon and bone-tendon insertion sites driving local Th17 T cell differentiation, and direct mechanical stress on entheseal tissue that amplifies the inflammatory cascade through innate lymphoid cells and gamma-delta T cells resident at entheseal sites. These pathways overlap significantly but are not identical, and their relative contributions to clinical severity differ between patients. Methotrexate's mechanism — dihydrofolate reductase inhibition reducing folate-dependent purine synthesis in rapidly proliferating T cells, and secondary adenosine accumulation at the A2A receptor suppressing macrophage TNF-alpha secretion — works across both compartments simultaneously. But the speed at which the two compartments respond differs: dermal keratinocyte hyperproliferation is more rapidly arrested by purine synthesis limitation because keratinocytes in psoriatic plaques have a dramatically elevated proliferation index (proliferating fraction up to tenfold above normal epidermis), making them highly sensitive to DHFR inhibition; the synovial T cell compartment has a lower proliferation rate and the synovial macrophages and entheseal stromal cells have independent TNF-alpha production pathways that are suppressed more slowly. The practical consequence is that skin may reach PASI near-zero at month four while DIP synovitis and enthesitis continue at a level sufficient to drive RANK-ligand-dependent osteoclast activation at the juxta-articular bone — producing psoriatic DIP erosions and osteolysis that accumulate silently and cannot be reversed once established. Annual x-ray of the DIP joints is required to detect this structural damage because erosions do not necessarily produce pain or visible swelling at the clinical threshold required for a patient to notice them. Stopping methotrexate when skin clears — the most natural patient decision — removes the suppression of both compartments simultaneously, causing DIP synovitis to flare back to its pre-treatment severity within six to ten weeks and accelerating the erosive damage that had been slowing on treatment. Spanish frame: 'El metotrexato no está funcionando solo para la piel. Está funcionando para la piel Y para las articulaciones al mismo tiempo, aunque usted no sienta que las articulaciones le están molestando ahora mismo. La psoriasis articular es una enfermedad de la inflamación que afecta tanto la piel como las articulaciones a través del mismo mecanismo — el sistema inmune activando unas células que se llaman linfocitos T-17 que liberan sustancias inflamatorias en la piel y en las articulaciones. El metotrexato frena esas células en los dos lugares a la vez. Cuando la piel mejora primero — lo cual es normal porque la piel responde más rápido que las articulaciones profundas — no significa que la inflamación en las articulaciones de los dedos ya desapareció. Las radiografías anuales son la única forma de saber si hay daño óseo acumulándose silenciosamente en las articulaciones. Parar el metotrexato cuando la piel está bien retira la protección de ambos — piel y articulaciones — al mismo tiempo.'

Why must biologic therapy continue in psoriatic arthritis after MRI shows resolution of sacroiliac joint inflammation?

In axial psoriatic arthritis, the MRI finding that drives treatment initiation — bone marrow edema at the sacroiliac joints on STIR sequences, representing acute inflammatory infiltration at the entheseal-bone interface — can completely resolve on biologic therapy while structural damage continues to progress through a partially independent pathway. This is one of the most consequential concepts for the psoriatic arthritis clinic nurse to convey, because MRI resolution feels like complete disease resolution to the patient. The acute inflammatory signal in axial psoriatic arthritis is driven primarily by IL-17A produced by Th17 cells and innate lymphoid cells at the entheseal insertion sites. IL-17A activates osteoclast precursors through RANK-ligand upregulation, drives neutrophil and macrophage infiltration into the marrow space adjacent to the sacroiliac joint entheseal complex, and promotes the endothelial activation visible as bone marrow edema on STIR MRI sequences. Secukinumab — a monoclonal antibody that directly neutralizes IL-17A by binding it before it can engage the IL-17RA/IL-17RC heterodimeric receptor — suppresses this acute inflammatory signal effectively: MEASURE 1 and MEASURE 2 trials demonstrated approximately 75 percent reduction in STIR bone marrow edema scores by week 24 in patients with active axial psoriatic arthritis. However, structural damage in axial disease — sacroiliac joint sclerosis, erosion, bridging, and spinal syndesmophyte formation — progresses through a distinct parallel pathway driven by Wnt-beta-catenin and bone morphogenetic protein signaling at the entheseal site. IL-17A indirectly promotes Wnt pathway activity by suppressing Dickkopf-1 (DKK1), a natural Wnt pathway inhibitor, allowing Wnt-driven osteoblast activation and new bone formation to proceed at entheseal sites that have experienced prior inflammatory damage. Critically, once Wnt-driven osteoblast activation is established at an entheseal site, it can continue at a reduced but non-zero rate even after the acute IL-17A signal is suppressed — because the physical microenvironment of the previously inflamed enthesis (altered extracellular matrix, residual macrophage activation, mechanical stress at the sacroiliac joint) sustains Wnt and BMP signaling through ligand-independent mechanisms. When secukinumab is stopped, IL-17A returns to pre-treatment levels within four to eight weeks as the drug clears (serum half-life approximately twenty-seven days). The acute inflammation returns, the Wnt suppression of DKK1 resumes, and structural progression accelerates. The annual x-ray is the tool that detects what MRI resolution conceals: new sclerosis at the sacroiliac joint margins, progressive medial joint space narrowing, and early entheseal calcification at spinal corners that the patient cannot feel because the process is occurring at the bone surface, not in the highly pain-sensitive synovial space. Spanish frame: 'La resonancia magnética mostró que la inflamación aguda en la articulación sacroilíaca — el edema que se veía en las imágenes — se resolvió con secukinumab. Eso es una excelente noticia. Pero hay un proceso diferente que pasa en esa articulación al mismo tiempo: el daño estructural — el endurecimiento del hueso, la erosión de los bordes de la articulación, la formación de puentes óseos. Ese proceso ocurre a través de una vía celular diferente que no depende completamente de la misma señal inflamatoria que el secukinumab bloquea. Los estudios clínicos muestran que cuando se para el secukinumab, la inflamación aguda vuelve en cuatro a ocho semanas — porque el medicamento sale del cuerpo y la inflamación subyacente sigue ahí. Con la inflamación devuelta, el daño estructural se acelera de nuevo. La radiografía anual de la pelvis y la columna es lo que detecta ese daño antes de que cause síntomas. Sentirse bien y la resonancia normal son señales de que el medicamento está funcionando — no de que la enfermedad desapareció.'

How do psoriatic arthritis clinic nurses explain that PsA is one disease, not psoriasis plus separate arthritis, in Spanish?

Many Spanish-speaking patients with psoriatic arthritis were diagnosed with skin psoriasis years or decades before developing joint symptoms. When the rheumatologist explains the diagnosis of psoriatic arthritis, patients often understand it as two separate coincidental diagnoses — psoriasis (a skin problem, managed by the dermatologist) and arthritis (a joint problem, managed by the rheumatologist) — rather than as one systemic immune-mediated disease with two tissue targets. This conceptual framing has direct treatment adherence consequences: a patient who understands them as separate may stop the joint medication when only the skin problem seems to be active, or vice versa. Psoriatic arthritis is immunopathologically unified: both skin plaque and joint synovitis are driven by the activation of the same adaptive immune population — Th17 T cells — through the same upstream pathway. In genetically susceptible individuals (with HLA-B*27 or HLA-C*06:02 and other susceptibility alleles), environmental or mechanical triggers activate dendritic cells and macrophages that produce IL-23. IL-23 drives naive CD4+ T cells and CD8+ T cells to differentiate into Th17 cells that secrete IL-17A, IL-17F, and TNF-alpha. These Th17 cells home to both the skin (where they drive keratinocyte hyperproliferation through the IL-17/IL-22 axis) and the joints (where they drive synovial inflammation through TNF-alpha and IL-17A acting on fibroblast-like synoviocytes and macrophages). It is the same Th17 cell population — differentiated by IL-23 upstream — acting at two anatomically separate tissue targets. Methotrexate, by inhibiting DHFR and reducing folate-dependent purine synthesis in T cells, suppresses this Th17 population systemically — reducing IL-17A and TNF-alpha production in both the skin and the joint simultaneously. Clinical remission in both compartments on methotrexate is pharmacological suppression of an ongoing Th17-driven process; stopping methotrexate allows Th17 activity to resume at both sites within weeks. The one-disease framing is clinically important also because patients with PsA have elevated risk of comorbidities — metabolic syndrome, cardiovascular disease, uveitis, inflammatory bowel disease — that are also driven by the same systemic Th17 dysregulation. Spanish frame: 'La psoriasis articular no es dos enfermedades que pasaron al mismo tiempo — la psoriasis de la piel de un lado, y la artritis de las articulaciones del otro. Es una sola enfermedad del sistema inmune que afecta dos lugares al mismo tiempo: la piel y las articulaciones. El origen es el mismo: unas células del sistema inmune llamadas linfocitos T-17 que se activan en exceso y liberan sustancias inflamatorias — interleucina-17 y factor de necrosis tumoral — en la piel y en las articulaciones. El metotrexato frena esas células en los dos lugares al mismo tiempo. Cuando usted para el metotrexato porque la piel está bien y las articulaciones no le duelen, esas células inflamatorias ya no están siendo frenadas. En seis a doce semanas, la inflamación vuelve en ambos lugares — a veces primero en la piel, a veces primero en las articulaciones, a veces en los dos. La enfermedad sigue siendo la misma. El medicamento la controlaba. Sin el medicamento, el control desaparece.'

What are the early warning signs of psoriatic arthritis structural damage that Spanish-speaking patients often miss and how do nurses explain them?

Psoriatic arthritis produces two types of structural damage that patients frequently miss because neither necessarily produces the dramatic acute pain of a synovitis flare: DIP joint erosion and osteolysis, and entheseal calcification and ankylosis. DIP erosion in psoriatic arthritis is mechanistically distinct from DIP osteoarthritis, which is far more common. In PsA, RANK-ligand produced by activated synovial T cells binds RANK on osteoclast precursors at the juxta-articular bone directly adjacent to the inflamed DIP joint synovium. Osteoclast differentiation and activation produces the characteristic punched-out erosions, cortical thinning, and — in severe cases — pencil-in-cup deformity (tapered distal phalanx in widened proximal cup) or arthritis mutilans (complete osteolysis of the proximal phalanx) that appear on hand x-ray. This process can advance measurably between annual x-rays without producing enough clinical inflammation for the patient to notice. A DIP joint may have mild intermittent swelling — dactylitis, or sausage digit, is the classic early sign — that the patient attributes to overuse or a minor injury. The structural damage accumulates regardless of whether swelling is perceived as severe. Entheseal damage — most commonly at the Achilles tendon insertion, plantar fascia, patellar tendon insertion, and at vertebral corner entheses — similarly may be painful during active inflammation but produces calcification, ossification, and ultimately entheseal bone formation (enthesophytes, syndesmophytes) that is asymptomatic as it establishes. Entheseal calcification at the Achilles insertion is visible on lateral ankle x-ray and represents irreversible structural change. Patients with PsA on treatment often report that they feel well and conclude treatment is not needed — without understanding that treatment is what is preventing detectable structural damage. The annual x-ray of hands and feet (GRAPPA 2021 recommendations) is the surveillance tool that detects erosion progression before the patient can perceive it. Spanish frame: 'El daño en las articulaciones de los dedos y en los tendones en la psoriasis articular pasa silenciosamente — no siempre duele lo suficiente como para que usted note que algo está cambiando. El primer signo puede ser un dedo que se hincha de forma pareja y se ve como una salchicha — eso se llama dactilitis. Pero incluso sin dactilitis, la inflamación dentro de la articulación puede estar activando células que erosionan el hueso lentamente. Por eso hacemos radiografías de las manos y los pies una vez al año — no porque tengamos que confirmar que hay dolor, sino porque queremos detectar el daño antes de que sea irreversible. Las erosiones óseas una vez establecidas no se revierten. El tratamiento previene el daño nuevo — no deshace el que ya ocurrió. Seguir con el tratamiento cuando se siente bien es exactamente lo que hace que no haya daño nuevo que detectar en la radiografía del próximo año.'

What are the key Spanish phrases for psoriatic arthritis clinic nurses explaining the skin-joint dissociation, MRI remission, and treatment continuation?

For explaining why skin clearance does not equal joint disease control: 'La piel y las articulaciones no siempre mejoran al mismo ritmo con el metotrexato. La piel puede mejorar primero — a veces mucho antes — mientras la inflamación en las articulaciones profundas todavía sigue activa, aunque no haya dolor intenso. El metotrexato está funcionando en los dos lugares. Parar el medicamento porque la piel está bien retira la protección de las articulaciones también.' (The skin and joints do not always improve at the same rate with methotrexate. The skin may improve first — sometimes much sooner — while the inflammation in the deep joints is still active, even without intense pain. Methotrexate is working in both places. Stopping the medication because the skin looks good also removes the protection from the joints.) For explaining MRI remission and continued structural risk: 'La resonancia magnética muestra la inflamación aguda — el edema en el hueso. Cuando el secukinumab bloquea la interleucina-17, esa inflamación aguda desaparece de la imagen. Pero hay un proceso diferente en esa misma articulación — el endurecimiento y la erosión del hueso — que tiene su propio mecanismo y no depende completamente de la misma señal inflamatoria. Sentirse bien y la resonancia normal son señales de que el medicamento funciona. No son señales de que se puede parar el medicamento.' (The MRI shows acute inflammation — bone marrow edema. When secukinumab blocks interleukin-17, that acute inflammation disappears from the image. But there is a different process in that same joint — bone hardening and erosion — that has its own mechanism and does not depend entirely on the same inflammatory signal. Feeling well and a normal MRI are signs that the medication is working. They are not signs that the medication can be stopped.) For explaining PsA as one disease: 'La psoriasis articular no es la psoriasis más la artritis — es una sola enfermedad del sistema inmune que aparece en dos lugares: la piel y las articulaciones. El metotrexato frena la misma célula inflamatoria en los dos lugares al mismo tiempo. Cuando el medicamento se para, esa célula vuelve a activarse en ambos lugares en pocas semanas.' (Psoriatic arthritis is not psoriasis plus arthritis — it is one immune system disease that appears in two places: the skin and the joints. Methotrexate suppresses the same inflammatory cell in both places simultaneously. When the medication is stopped, that cell reactivates in both places within weeks.) For explaining the role of annual x-ray surveillance: 'Las radiografías anuales de las manos y los pies no son para confirmar que le duelen — son para detectar daño óseo antes de que usted pueda sentirlo. Las erosiones que se forman en los huesos de los dedos con la psoriasis articular no duelen en cada momento en que se están formando. Las detectamos en la radiografía un año antes de que causen un cambio que usted noto. Por eso no se saltan.' (Annual x-rays of the hands and feet are not to confirm that they hurt — they are to detect bone damage before you can feel it. The erosions that form in the finger bones with psoriatic arthritis do not hurt at every moment they are forming. We detect them on x-ray a year before they cause a change you notice. That is why they are not skipped.) For clarifying that methotrexate is not a cancer chemotherapy at the rheumatology dose: 'El metotrexato que usamos para la psoriasis articular es una dosis muy diferente a la que se usa para el cáncer. Para el cáncer se usan dosis de cientos o miles de miligramos por metro cuadrado por vía intravenosa. Para la psoriasis articular usamos quince a veinticinco miligramos por semana — una dosis que se ha usado por décadas en millones de pacientes con artritis sin aumentar el riesgo de cáncer. Es un medicamento que suprime la inflamación, no un medicamento de quimioterapia en la forma en que usted lo está pensando.' (The methotrexate we use for psoriatic arthritis is a very different dose from what is used for cancer. For cancer, doses of hundreds or thousands of milligrams per square meter are used intravenously. For psoriatic arthritis we use fifteen to twenty-five milligrams per week — a dose that has been used for decades in millions of arthritis patients without increasing cancer risk. It is a medication that suppresses inflammation, not a chemotherapy medication in the way you are thinking.)

November 3, 2026 · Rheumatology, Psoriatic Arthritis, Dermatology

Spanish for psoriatic arthritis clinic nurses — the patient who stopped methotrexate when the skin cleared not knowing DIP joint erosions from synovitis-driven osteoclast activation accumulate silently even with PASI zero; the patient who stopped secukinumab when the MRI showed no active sacroiliac joint inflammation not knowing structural damage via Wnt-pathway osteoblast activation continues independent of bone marrow edema; and the patient who stopped methotrexate reasoning the arthritis was resolved not knowing psoriatic arthritis is one disease at the skin-joint intersection and MTX suppresses both compartments through the same adenosine-pathway mechanism simultaneously

Three conversations for psoriatic arthritis clinic nurses: Alejandro Vásquez-Morales, 48, Dallas, who stopped methotrexate when PASI dropped to 2 not knowing joint disease responds more slowly than skin and DIP erosions progress silently; Sofía Ramírez-Espinoza, 39, Miami, who stopped secukinumab when MRI sacroiliitis resolved not knowing structural damage via Wnt-pathway signaling continues after acute inflammation is suppressed; and Rodrigo Fuentes-Villanueva, 55, Phoenix, who stopped methotrexate reasoning both skin and joints were clinically quiet not knowing PsA is one disease and stopping removes suppression from both compartments simultaneously.

Psoriatic arthritis confronts the clinic nurse with a category of treatment failure built on a logical foundation: the patient uses the visible, measurable indicators of disease — the skin, the swollen joint, the MRI image — to conclude that disease is resolved and treatment is no longer needed. The skin clears. The joint stops hurting. The MRI looks normal. Each observation is real. Each inference from that observation is mechanistically incorrect in a specific way that the psoriatic arthritis clinic nurse is uniquely positioned to address.

Psoriatic arthritis is a seronegative inflammatory arthropathy driven by dysregulated Th17 immune activity at two anatomically separate tissue targets: the skin and the musculoskeletal system. It is not psoriasis with incidental joint involvement, and it is not a joint disease that happens to occur in patients with psoriasis. It is one disease with two faces, both driven by the same upstream IL-23/Th17 pathway, both requiring the same continuous pharmacological suppression to prevent irreversible structural damage at both targets. The challenge for the psoriatic arthritis clinic nurse is that the structural damage at the joint — DIP erosions, entheseal calcification, sacroiliac ankylosis — accumulates silently between observable symptoms, makes itself known only on annual x-ray, and cannot be reversed once established. The decisions that allow that damage to accumulate are made at moments of apparent wellness.

Three patients, three mechanistically distinct errors, three conversations that can prevent decades of progressive joint destruction and disability.

Scenario 1: Alejandro Vásquez-Morales — 48 years old, Dallas, Texas

Alejandro Vásquez-Morales was a forty-eight-year-old commercial electrician in Dallas who had had plaque psoriasis since his early thirties — a diagnosis he had lived with for fifteen years as a skin condition, managed intermittently with topical steroids and a short course of phototherapy. He had long known to check his elbows and scalp in the morning. At forty-six, he began noticing something different: the joints at the tips of his fingers — the distal interphalangeal joints — were swollen intermittently, stiff in the mornings, and occasionally warm to the touch. His right index finger had been swollen throughout for three months — uniformly, from the base to the tip, resembling a sausage. His left Achilles had been painful at its insertion into the heel for six months, worse with his first steps in the morning and after long days on scaffolding.

His dermatologist recognized the pattern and referred him to rheumatology. The rheumatology evaluation confirmed psoriatic arthritis: bilateral DIP joint synovitis on examination, right index dactylitis, left Achilles enthesopathy, and plaque psoriasis with PASI fourteen involving both elbows and the scalp. Hand x-rays showed early marginal erosions at the right index DIP joint and cortical thinning at the distal phalanx. His rheumatologist prescribed methotrexate fifteen milligrams weekly with folic acid supplementation.

Four months later, Alejandro’s skin was dramatically improved. His elbow plaques had thinned to faint erythematous patches — PASI two. The right index dactylitis had partially resolved. The left Achilles was less painful on morning walking. He felt better than he had in two years. He stopped methotrexate on his own, between visits. When the rheumatology clinic nurse, Elena Cisneros-Ramírez, called to confirm his follow-up appointment, Alejandro told her what had happened.

“La piel ya está casi limpia — PASI dos, me dijeron la última vez. Me siento bien. Ya no me parece que necesito tomar el metotrexato indefinidamente — es un medicamento fuerte y si la enfermedad ya respondió, para qué seguir.”

(The skin is almost clear — PASI two, they told me last time. I feel well. I do not think I need to take methotrexate indefinitely — it is a strong medication and if the disease already responded, why continue.)

Nurse Cisneros-Ramírez asked him to come in for a conversation before his formal appointment. She had seen this reasoning before and knew that Alejandro’s early DIP erosions made this decision particularly consequential.

“Don Alejandro, me alegra mucho que la piel esté mejor. Eso es exactamente lo que esperábamos del metotrexato. Pero quiero explicarle algo importante sobre cómo funciona su enfermedad — porque la psoriasis articular funciona de una manera que hace que la piel pueda verse casi normal mientras las articulaciones de los dedos aún tienen inflamación activa por dentro.”

(Don Alejandro, I am very glad the skin is better. That is exactly what we expected from methotrexate. But I want to explain something important about how your disease works — because psoriatic arthritis works in a way that allows the skin to look almost normal while the joints of the fingers still have active inflammation inside.)

Alejandro: “¿Cómo puede tener inflamación si ya no me duele tanto?”

“Esa es exactamente la pregunta correcta. En la psoriasis articular, la inflamación en las articulaciones pequeñas de los dedos — las articulaciones distales, las de la punta del dedo — puede estar activándose células que dañan el hueso incluso cuando el dolor es leve o intermitente. No todo el daño articular produce dolor constante que usted siente claramente. A veces el daño se acumula silenciosamente en el interior del hueso mientras usted trabaja, vive su vida, y no tiene un dolor severo que le diga que algo está pasando. Por eso tenemos radiografías anuales de las manos — para detectar ese daño antes de que usted lo pueda sentir.”

(That is exactly the right question. In psoriatic arthritis, the inflammation in the small joints of the fingers — the distal joints, the ones at the fingertip — can be activating cells that damage the bone even when pain is mild or intermittent. Not all joint damage produces constant pain that you clearly feel. Sometimes the damage accumulates silently inside the bone while you work, live your life, and do not have a severe pain telling you something is happening. That is why we have annual x-rays of the hands — to detect that damage before you can feel it.)

Alejandro frowned. “¿Y la radiografía anterior mostró algo?”

“Sí. La radiografía de sus manos del mes pasado mostró erosiones marginales tempranas en la articulación del dedo índice derecho — el que estuvo hinchado como salchicha. Las erosiones son pequeñas irregularidades en el borde del hueso causadas por unas células — osteoclastos — que se activan cuando hay inflamación en el tejido que rodea al hueso. Una vez que el hueso se erosiona, no se recupera. No se puede deshacer el daño que ya ocurrió. Lo que podemos hacer es evitar que haya más daño. Eso es lo que está haciendo el metotrexato.”

(Yes. The x-ray of your hands from last month showed early marginal erosions at the right index finger joint — the one that was swollen like a sausage. Erosions are small irregularities at the edge of the bone caused by certain cells — osteoclasts — that are activated when there is inflammation in the tissue surrounding the bone. Once the bone erodes, it does not recover. The damage that already occurred cannot be undone. What we can do is prevent more damage. That is what methotrexate is doing.)

Alejandro sat quietly. “¿El metotrexato previene que el hueso siga erosionándose?”

“Sí. El metotrexato frena las células inflamatorias — los linfocitos T que producen las sustancias que activan los osteoclastos. Cuando usted toma el metotrexato, esas células están frenadas en las articulaciones y en la piel al mismo tiempo. Por eso la piel mejoró con el mismo medicamento que frena el daño articular. Son el mismo tipo de célula inflamatoria, y el metotrexato las frena en los dos lugares.”

(Yes. Methotrexate suppresses the inflammatory cells — the T lymphocytes that produce the substances that activate osteoclasts. When you take methotrexate, those cells are suppressed in the joints and in the skin at the same time. That is why the skin improved with the same medication that suppresses joint damage. They are the same type of inflammatory cell, and methotrexate suppresses them in both places.)

“Lo que pasa es que la piel responde primero — más rápido — porque las células de la piel que estaban proliferando en exceso detienen su crecimiento rápidamente cuando el metotrexato bloquea su capacidad de dividirse. Las articulaciones profundas tienen una población de células inflamatorias que se divide más lentamente y responde más gradualmente. A los cuatro meses, la piel está casi limpia — PASI dos — pero el tejido sinovial de las articulaciones distales aún puede tener inflamación residual suficiente para activar osteoclastos. Si para el metotrexato ahora, esas células inflamatorias regresan a plena actividad en seis a diez semanas. El dolor que usted siente puede no ser el primer signo de que eso está pasando — la radiografía del próximo año puede ser la primera señal.”

(What happens is that the skin responds first — faster — because the skin cells that were proliferating in excess quickly stop growing when methotrexate blocks their ability to divide. The deep joints have a population of inflammatory cells that divides more slowly and responds more gradually. At four months, the skin is nearly clear — PASI two — but the synovial tissue of the distal joints may still have enough residual inflammation to activate osteoclasts. If you stop methotrexate now, those inflammatory cells return to full activity in six to ten weeks. The pain you feel may not be the first sign that this is happening — next year’s x-ray may be the first signal.)

Alejandro: “¿Entonces la piel limpia no significa que las articulaciones también están bien?”

“Exacto. La piel y las articulaciones no siempre responden al mismo ritmo. La piel puede verse bien mientras las articulaciones aún están trabajando para llegar a la misma calma inflamatoria. Y cuando el daño articular es silencioso — como en su caso, con erosiones tempranas que no le dan un dolor severo constante — la única forma de saber cómo están las articulaciones es la radiografía anual y la evaluación clínica periódica. Necesitamos mantener el metotrexato mientras seguimos evaluando si la respuesta articular ha llegado al mismo nivel de control que la respuesta de la piel.”

(Exactly. The skin and joints do not always respond at the same pace. The skin may look good while the joints are still working toward the same inflammatory calm. And when the joint damage is silent — as in your case, with early erosions that do not give you constant severe pain — the only way to know how the joints are doing is the annual x-ray and periodic clinical evaluation. We need to maintain methotrexate while we continue evaluating whether the joint response has reached the same level of control as the skin response.)

Alejandro: “¿Y si el metotrexato no llega a controlar las articulaciones lo suficiente?”

“Si la respuesta articular no es adecuada — si las erosiones siguen progresando en la radiografía anual o si el tejido sinovial sigue estando activo — hay una siguiente línea de tratamiento: los biológicos, que bloquean directamente las sustancias inflamatorias específicas — la interleucina-17 o el factor de necrosis tumoral — con mayor precisión que el metotrexato. Pero esa decisión se toma en colaboración con usted y con el reumátologo, con datos reales de radiografías y evaluaciones clínicas. Lo que no podemos hacer es tomar esa decisión sin datos, parando el metotrexato cuando la piel está bien y esperando a que aparezca algo grave.”

(If the joint response is not adequate — if erosions continue progressing on the annual x-ray or if the synovial tissue remains active — there is a next line of treatment: biologics, which directly block the specific inflammatory substances — interleukin-17 or tumor necrosis factor — with greater precision than methotrexate. But that decision is made together with you and with the rheumatologist, with real data from x-rays and clinical evaluations. What we cannot do is make that decision without data, stopping methotrexate when the skin looks good and waiting for something serious to appear.)

Alejandro restarted methotrexate fifteen milligrams weekly. At month twelve — eight months after the conversation and restart — his hand x-ray showed no new erosions compared to month four. His DIP synovitis had quieted on clinical examination. His left Achilles enthesopathy had resolved. His PASI remained below three. The rheumatologist decided to continue methotrexate and add a brief course of intra-articular corticosteroid to one persistently active DIP joint while titrating methotrexate to twenty milligrams weekly. At month twenty-four: no new erosions, PASI one, no dactylitis, normal Achilles insertion on clinical examination.

Scenario 2: Sofía Ramírez-Espinoza — 39 years old, Miami, Florida

Sofía Ramírez-Espinoza was a thirty-nine-year-old bilingual medical interpreter in Miami who had been diagnosed with psoriatic arthritis at age thirty-four — axial involvement with bilateral sacroiliitis plus peripheral asymmetric oligoarthritis affecting the right knee and left ankle. She had no skin psoriasis visible at diagnosis (PsA can precede or occur without visible skin psoriasis in approximately fifteen percent of cases), though her older sister had plaque psoriasis. Her HLA-B*27 was negative; sacroiliac joint MRI at diagnosis showed bilateral bone marrow edema on STIR sequences, grade II sacroiliitis by modified New York criteria bilaterally.

She had been started on adalimumab, a TNF-alpha inhibitor, with initial response but recurrent injection site reactions leading to discontinuation at month fourteen. She was switched to secukinumab three hundred milligrams monthly — an IL-17A monoclonal antibody — at age thirty-six. The response was excellent: within eight months her inflammatory back pain score had dropped from six of ten to one of ten, morning stiffness resolved from ninety minutes to under fifteen minutes, and her peripheral knee and ankle synovitis had completely resolved clinically. At month twelve, a surveillance MRI of the sacroiliac joints showed complete resolution of bilateral bone marrow edema on STIR sequences — the imaging remission that the rheumatologist had been targeting.

Sofía reviewed the MRI report herself — her English was fluent — and saw the phrase “no evidence of active sacroiliitis.” She stopped secukinumab on her own three weeks later, reasoning that if there was no evidence of inflammation in the joint, she no longer needed the medication. She told the clinic at her next scheduled call, five months later.

“Llevo ya cinco meses sin el secukinumab. Me sientó bien, la resonancia no mostró inflamación, y no quiero estar en un biológico sin necesidad. Quiero ver si el cuerpo se mantiene en remisión por sí solo.”

(I have been without secukinumab for five months now. I feel well, the MRI showed no inflammation, and I do not want to be on a biologic unnecessarily. I want to see if the body maintains remission on its own.)

The PsA clinic nurse, Marco Flores-Domínguez, asked to schedule a video visit that afternoon. Sofía’s case required careful explanation: she was medically literate, had read the MRI report, and had made a decision with a logic that was internally coherent. He needed to explain the gap between MRI remission and structural stability in axial PsA without being dismissive of her reasoning.

“Sofía, gracias por decirme esto directamente. Voy a explicarle algo que es importante entender sobre cómo funciona la resonancia magnética en la articulación sacroilíaca — y por qué la desaparición de la inflamación en la resonancia no equivale a que la enfermedad haya desaparecido o a que el tratamiento ya no sea necesario.”

(Sofía, thank you for telling me this directly. I am going to explain something important about how MRI works in the sacroiliac joint — and why the disappearance of inflammation on MRI is not the same as the disease having disappeared or the treatment no longer being needed.)

Sofía: “La resonancia dijo ‘no hay evidencia de sacroiliitis activa.’ Eso parece bastante claro.”

“Y es correcto — en ese momento, en esa imagen, no había edema de médula ósea activo en la articulación. Ese edema representa inflamación aguda — glóbulos blancos y líquido inflamatorio dentro del hueso adyacente a la articulación. El secukinumab bloquea la interleucina-17, que es la sustancia inflamatoria que activa esa inflamación aguda. Cuando la interleucina-17 está bloqueada, el edema desaparece — exactamente como muestra la resonancia. Eso es lo que el medicamento está haciendo.”

(And it is correct — at that moment, in that image, there was no active bone marrow edema in the joint. That edema represents acute inflammation — white blood cells and inflammatory fluid inside the bone adjacent to the joint. Secukinumab blocks interleukin-17, which is the inflammatory substance that activates that acute inflammation. When interleukin-17 is blocked, the edema disappears — exactly as the MRI shows. That is what the medication is doing.)

“Pero hay un proceso diferente en esa misma articulación que la resonancia magnética estándar no mide bien: el daño estructural — el endurecimiento del hueso en los bordes de la articulación, la erosión de la superficie articular, la formación de puentes óseos que pueden llevar a la fusión de la articulación. Ese proceso ocurre a través de una vía diferente: osteoblastos que forman hueso nuevo en respuesta a una señal llamada la vía Wnt, que se activa en los tejidos que han tenido inflamación. Esa vía tiene su propia mecánica: una vez que ha sido activada por inflamación previa, puede seguir activa a un nivel bajo incluso cuando la inflamación aguda se ha resuelto. No depende completamente de la interleucina-17 para seguir funcionando.”

(But there is a different process in that same joint that standard MRI does not measure well: structural damage — hardening of the bone at the joint edges, erosion of the joint surface, formation of bony bridges that can lead to joint fusion. That process occurs through a different pathway: osteoblasts forming new bone in response to a signal called the Wnt pathway, which is activated in tissues that have had inflammation. That pathway has its own mechanics: once it has been activated by prior inflammation, it can continue active at a low level even when the acute inflammation has resolved. It does not depend entirely on interleukin-17 to continue functioning.)

Sofía, who understood medical concepts well: “¿O sea que la resonancia que muestra inflamación es la señal aguda, pero hay daño estructural que ocurre por otra vía que la resonancia no detecta bien?”

“Exactamente. La resonancia es excepcional para ver el edema del hueso — la inflamación aguda. Para ver el daño estructural ya establecido, la radiografía simple y la tomografía son mejores, porque muestran el hueso directamente. Y los estudios clínicos en psoriasis articular axial han mostrado que los pacientes pueden seguir progresando en daño estructural en la articulación sacroilíaca y en la columna incluso durante períodos de inflamación baja en la resonancia. El problema es que ese daño estructural no produce dolor hasta que está muy avanzado. Una articulación sacroilíaca que se está volviendo rígida por formación de hueso nuevo puede sentirse incluso mejor que una en inflamación aguda — hasta que la fusión está completa y la movilidad se pierde de forma permanente.”

(Exactly. MRI is exceptional for seeing bone marrow edema — acute inflammation. For seeing already-established structural damage, plain x-ray and CT are better, because they show the bone directly. And clinical studies in axial psoriatic arthritis have shown that patients can continue progressing in structural damage at the sacroiliac joint and in the spine even during periods of low inflammation on MRI. The problem is that structural damage does not produce pain until it is very advanced. A sacroiliac joint that is becoming rigid due to new bone formation can feel even better than one in acute inflammation — until fusion is complete and mobility is permanently lost.)

Sofía was quiet for a moment. “¿Y cuando paré el secukinumab, la interleucina-17 regresó a sus niveles originales?”

“Sí. El secukinumab tiene una vida media de aproximadamente veintisiete días en la sangre. Después de cinco meses sin el medicamento, su nivel en sangre está prácticamente a cero. La interleucina-17 subyacente — producida por sus linfocitos T-17 que siguen siendo la causa de su enfermedad — regresará a niveles similares a los del inicio. La inflamación aguda puede estar regresando silenciosamente ahora mismo, aunque usted se sienta bien, porque el dolor de la sacroiliitis activa puede tardar semanas en manifestarse después de que el nivel del medicamento cae.”

(Yes. Secukinumab has a half-life of approximately twenty-seven days in the blood. After five months without the medication, its blood level is practically zero. The underlying interleukin-17 — produced by your Th17 lymphocytes that remain the cause of your disease — will return to levels similar to the beginning. Acute inflammation may be returning silently right now, even though you feel well, because the pain of active sacroiliitis can take weeks to manifest after the drug level falls.)

The clinic ordered a pelvic x-ray that afternoon. The results showed new sacroiliac joint sclerosis at both joints compared to the pelvic x-ray from two years prior — new medial joint space narrowing on the right, early subchondral sclerosis bilaterally. No erosions yet, but measurable structural change in the twenty-two months since the diagnosis. The secukinumab-free period of five months had allowed the Wnt-pathway osteoblast activation to proceed without suppression.

Sofía: “¿El daño que ya apareció en la radiografía se puede revertir?”

“No. El hueso que se formó en exceso y la esclerosis que se ve en la radiografía son cambios permanentes. Lo que podemos hacer es reiniciar el secukinumab para suprimir la inflamación aguda y reducir el estímulo para que ese proceso estructural continúe. Los estudios clínicos muestran que el tratamiento biológico continuo reduce la tasa de progresión estructural comparado con el tratamiento intermitente o discontinuado. No lo para completamente en todos los pacientes, pero lo enlentece significativamente. El objetivo es que la radiografía del próximo año no muestre más cambios de los que hay ahora.”

(No. The excess bone that formed and the sclerosis visible on x-ray are permanent changes. What we can do is restart secukinumab to suppress the acute inflammation and reduce the stimulus for that structural process to continue. Clinical studies show that continuous biologic treatment reduces the rate of structural progression compared to intermittent or discontinued treatment. It does not stop it completely in all patients, but it slows it significantly. The goal is for next year’s x-ray to show no more changes than there are now.)

Sofía restarted secukinumab three hundred milligrams monthly. Inflammatory back pain returned to a score of one of ten within eight weeks of reinitiation. Annual pelvic x-ray at twelve months post-restart: no new sclerosis beyond the changes seen at the five-month stop. MRI at eighteen months post-restart: bilateral sacroiliac bone marrow edema again resolved. The structural changes from the five-month discontinuation were permanent, but no new changes were detected on continued treatment.

Scenario 3: Rodrigo Fuentes-Villanueva — 55 years old, Phoenix, Arizona

Rodrigo Fuentes-Villanueva was a fifty-five-year-old retired landscaper in Phoenix who had had plaque psoriasis for fifteen years, diagnosed at age forty. His psoriasis had been managed by his dermatologist with topical steroids, apremilast for two years (discontinued for gastrointestinal side effects), and more recently UV phototherapy for severe scalp and trunk involvement. At age fifty-four — one year before his presentation to the psoriatic arthritis clinic — he developed bilateral DIP joint swelling and stiffness, right wrist synovitis, and right Achilles enthesopathy that prevented him from his morning walks. His primary care physician ordered rheumatoid factor (negative) and anti-CCP (negative) and referred him to rheumatology.

The rheumatology evaluation confirmed psoriatic arthritis: bilateral DIP synovitis, right wrist tenosynovitis, right Achilles enthesopathy, and plaque psoriasis with PASI eight involving the scalp, trunk, and bilateral lower legs. Hand and foot x-rays showed no erosions at presentation — this was an early PsA case with an opportunity for effective structural damage prevention. The rheumatologist prescribed methotrexate fifteen milligrams weekly, explaining that it would address both the skin and the joints simultaneously.

At month four, Rodrigo’s skin had improved substantially — PASI one, scalp nearly clear. His DIP joints were no longer visibly swollen on examination. His right wrist synovitis had resolved. His Achilles, he said, was “much better — I can walk in the morning again.” He felt the best he had in a year and a half.

He did not come to his month-six appointment. He did not return the nurse’s calls for two weeks. When the PsA clinic nurse, Isabel Montoya-Cervantes, finally reached him, he explained what had happened.

“Decidí parar el metotrexato hace seis semanas. Me siento bien — la piel está casi limpia, las articulaciones ya no me duelen. Y honestamente, me preocupa tomar un medicamento de quimioterapia por tiempo indefinido. Mi hermano tuvo cáncer y conozco los medicamentos de quimio. No me parece correcto tomarlos cuando no los necesito.”

(I decided to stop methotrexate six weeks ago. I feel well — the skin is almost clear, the joints no longer hurt. And honestly, I am worried about taking a chemotherapy medication indefinitely. My brother had cancer and I know chemo medications. It does not seem right to me to take them when I do not need them.)

Nurse Montoya-Cervantes had two things to address: the clinical reasoning about needing the medication, and the fear about methotrexate as a chemotherapy drug. She started with the second, because it was the more urgent barrier.

“Don Rodrigo, entiendo completamente la preocupación. Cuando alguien en la familia pasó por quimioterapia, la palabra ‘metotrexato’ en el mismo contexto es muy perturbadora, y tiene todo el sentido que eso lo preocupe. Quiero ser muy claro con usted sobre la diferencia — porque es una diferencia muy grande.”

(Don Rodrigo, I completely understand the concern. When someone in the family went through chemotherapy, the word “methotrexate” in the same context is very disturbing, and it makes complete sense that this worries you. I want to be very clear with you about the difference — because it is a very large difference.)

“El metotrexato que se usa para tratar cánceres — como leucemia, linfoma, algunos tumores sólidos — se da en dosis de cientos o miles de miligramos por metro cuadrado de superficie corporal, por vía intravenosa, en ciclos de varios días. Es una dosis pensada para destruir células que se dividen rápidamente, como las células cancerosas, y los efectos secundarios que usted conoce de ver a su hermano — la caída del cabello severa, las náuseas intensas, la inmunosupresión profunda — son efectos de esas dosis muy altas.”

(The methotrexate used to treat cancers — like leukemia, lymphoma, some solid tumors — is given in doses of hundreds or thousands of milligrams per square meter of body surface area, intravenously, in cycles of several days. It is a dose designed to destroy rapidly dividing cells, like cancer cells, and the side effects you know from watching your brother — severe hair loss, intense nausea, deep immunosuppression — are effects of those very high doses.)

“El metotrexato que le recetamos para la psoriasis articular es quince miligramos por semana — en total, en la semana entera — tomado por vía oral una vez a la semana. Es una dosis que es entre diez veces y cien veces menor a la que se usa en quimioterapia. Ha sido usada durante décadas — desde la década de los sesenta — en millones de pacientes con artritis reumatoide, psoriasis, y psoriasis articular. Las revisiones de seguridad a largo plazo, con más de cuarenta años de datos, no muestran un aumento en el riesgo de cáncer en pacientes que toman metotrexato a dosis bajas para enfermedades inflamatorias. El medicamento que su hermano tomó y el medicamento que usted toma tienen el mismo nombre. Las dosis y los efectos son fundamentalmente diferentes.”

(The methotrexate we prescribe for psoriatic arthritis is fifteen milligrams per week — in total, over the entire week — taken orally once a week. That is a dose that is ten to one hundred times lower than what is used in chemotherapy. It has been used for decades — since the 1960s — in millions of patients with rheumatoid arthritis, psoriasis, and psoriatic arthritis. Long-term safety reviews, with more than forty years of data, do not show an increase in cancer risk in patients taking low-dose methotrexate for inflammatory diseases. The medication your brother took and the medication you take have the same name. The doses and effects are fundamentally different.)

Rodrigo: “¿Y el riesgo del hígado?”

“Hay un riesgo de toxicidad hepática con metotrexato a largo plazo, y por eso monitoreamos las enzimas del hígado en cada análisis de sangre regular. Las pautas actuales indican que con las enzimas normales, sin factores de riesgo adicionales — como consumo alto de alcohol, hepatitis viral, esteatosis hepática importante — el riesgo de daño hepático significativo con metotrexato a las dosis que usted toma es bajo y manejable con monitoreo. Por eso los análisis son importantes. No es un medicamento que se toma sin vigilancia — se toma con vigilancia periódica para detectar cualquier señal temprana. En sus análisis de los últimos cuatro meses, las enzimas del hígado estuvieron siempre dentro de lo normal.”

(There is a risk of hepatic toxicity with long-term methotrexate, and that is why we monitor liver enzymes in each regular blood test. Current guidelines indicate that with normal enzymes, without additional risk factors — like high alcohol use, viral hepatitis, significant hepatic steatosis — the risk of significant liver damage with methotrexate at the doses you are taking is low and manageable with monitoring. That is why the blood tests are important. It is not a medication taken without surveillance — it is taken with periodic surveillance to detect any early signal. In your blood tests over the last four months, liver enzymes were always within normal range.)

Rodrigo was quiet. “Eso me tranquiliza. Pero todavía no entiendo por qué lo necesito si la piel está bien y las articulaciones no me duelen.”

“Esa es la pregunta que más escucho de pacientes que están respondiendo bien al tratamiento, y tiene todo el sentido hacerla. Aquí está lo que necesita entender: cuando se siente bien y la piel está limpia — eso no significa que la psoriasis articular desapareció. Significa que el metotrexato está frenando la enfermedad. La enfermedad sigue ahí. El sistema inmune de usted tiene una programación heredada que activa células inflamatorias llamadas linfocitos T-17 que atacan la piel y las articulaciones. El metotrexato no cambia esa programación — la frena mientras se está tomando. Cuando para el metotrexato, la programación vuelve a activarse en seis a doce semanas.”

(That is the question I hear most often from patients who are responding well to treatment, and it makes complete sense to ask it. Here is what you need to understand: when you feel well and the skin is clear — that does not mean psoriatic arthritis has disappeared. It means methotrexate is suppressing the disease. The disease is still there. Your immune system has an inherited programming that activates inflammatory cells called Th17 lymphocytes that attack the skin and the joints. Methotrexate does not change that programming — it suppresses it while being taken. When you stop methotrexate, the programming reactivates within six to twelve weeks.)

“Y aquí hay algo más importante en su caso específico: usted presentó con psoriasis articular en la etapa más favorable posible — sin erosiones en las radiografías al principio. Eso significa que tenía ventana de oportunidad para prevenir el daño estructural antes de que empezara. El metotrexato en ese momento está haciendo algo que no se puede deshacer: prevenir las erosiones óseas que habrían ocurrido si la inflamación hubiera continuado sin control. Las erosiones óseas en la psoriasis articular, una vez formadas, son permanentes. Parar el metotrexato ahora — precisamente cuando está funcionando antes de que haya daño — es retirar la protección en el momento de mayor oportunidad.”

(And there is something more important in your specific case: you presented with psoriatic arthritis at the most favorable possible stage — without erosions on x-rays at the start. That means you had a window of opportunity to prevent structural damage before it began. Methotrexate at that moment is doing something that cannot be undone: preventing the bone erosions that would have occurred if inflammation had continued uncontrolled. Bone erosions in psoriatic arthritis, once formed, are permanent. Stopping methotrexate now — precisely when it is working before there is damage — is withdrawing protection at the moment of greatest opportunity.)

Rodrigo: “¿Y el hecho de que ya llevo seis semanas sin el medicamento — ya hay daño nuevo?”

“No lo sabemos todavía. Necesitamos hacer una radiografía de manos y pies ahora mismo para tener una línea de comparación. Seis semanas es un período en el que la inflamación puede haber regresado en las articulaciones aunque usted no tenga todavía los síntomas claros. Si tiene erosiones comparadas con la radiografía inicial, eso nos dice que necesitamos ser más agresivos con el tratamiento. Si no tiene cambios, volvemos a empezar desde el mismo punto — con la oportunidad aún presente.”

(We do not know yet. We need to do an x-ray of the hands and feet right now to have a line of comparison. Six weeks is a period in which inflammation may have returned in the joints even though you do not yet have clear symptoms. If you have erosions compared to the initial x-ray, that tells us we need to be more aggressive with treatment. If there are no changes, we start again from the same point — with the opportunity still present.)

Rodrigo agreed to the x-ray that afternoon. Compared to the baseline x-ray twelve months earlier, no new erosions were detected — six weeks had not been long enough for significant structural damage to accumulate. He restarted methotrexate fifteen milligrams weekly with folic acid. Nurse Montoya-Cervantes added explicit explanation to his discharge summary about the distinction between cancer-dose and low-dose methotrexate, documented his brother’s cancer history in the chart as the source of his concern, and scheduled his month-three and month-six x-ray and blood work follow-ups in advance so Rodrigo had concrete dates to return to.

At month twelve post-restart: PASI one, no active DIP synovitis on examination, no Achilles enthesopathy, hand and foot x-rays showing no erosions. At month twenty-four: disease remained stable. The structural damage window had been successfully protected.

What psoriatic arthritis clinic nurses working with Spanish-speaking patients need to know about these three conversations

The three scenarios above share a structural pattern that appears across psoriatic arthritis clinic populations: the patient uses the most intuitive measure of disease activity — visible skin, perceived joint pain, imaging result — to make a decision about medication that is mechanistically incorrect because the measure they are using is incomplete. Alejandro used skin clearance. Sofía used MRI resolution. Rodrigo used the absence of current symptoms. Each indicator was real. Each inference from the indicator was wrong in a specific, teachable way.

For Alejandro, skin clearance at month four indicated successful treatment. The missing piece was that skin and joint respond to methotrexate at different rates because dermal keratinocyte hyperproliferation is more rapidly arrested by DHFR inhibition than the slower-cycling synovial T cell compartment — and that the silent DIP erosions from RANK-ligand-dependent osteoclast activation accumulate regardless of whether skin PASI reaches zero. Methotrexate suppresses both simultaneously; stopping it when skin clears removes both suppressive effects.

For Sofía, MRI resolution of bone marrow edema indicated complete disease control. The missing piece was that bone marrow edema represents the acute IL-17A-driven inflammatory signal, while structural damage progression via Wnt-pathway and BMP-driven osteoblast activation is a parallel process that continues at reduced but non-zero activity even after the acute signal is suppressed — and resumes at full rate when secukinumab is withdrawn and IL-17A returns. Annual x-ray detects this structural progression that MRI and symptoms conceal.

For Rodrigo, the absence of symptoms indicated disease resolution and raised the question of why to continue a medication with perceived toxicity. The missing piece was twofold: first, that clinical remission on methotrexate is pharmacological suppression of an ongoing Th17-driven process that resumes on drug withdrawal; and second, that low-dose weekly methotrexate for inflammatory disease and high-dose intravenous methotrexate for cancer are the same molecule at doses with fundamentally different risk profiles — a distinction that is clinically critical to make explicit when the patient has direct personal experience with the cancer context.

The psoriatic arthritis disease model that the clinic nurse must communicate in Spanish can be summarized as a continuous Th17-driven inflammation affecting both skin and joint, requiring continuous pharmacological suppression to prevent irreversible structural damage that accumulates silently between observable symptoms. The skin is the most visible indicator and the most rapid responder; the joints accumulate damage without proportional pain; the bone is the ultimate victim of unchecked inflammation; and the annual x-ray — not the patient’s symptom report alone — is the surveillance tool that detects the invisible accumulation before it becomes irreversible.

The five markers that Spanish-speaking patients with psoriatic arthritis should understand to make informed decisions about their treatment:

First, the skin and joints are one disease, one treatment. “La piel y las articulaciones son la misma enfermedad. El medicamento trabaja en los dos lugares al mismo tiempo. Cuando la piel está bien, el medicamento está trabajando. Cuando para el medicamento porque la piel está bien, para la protección de las articulaciones también.” (The skin and joints are the same disease. The medication works in both places at the same time. When the skin looks good, the medication is working. When you stop the medication because the skin looks good, you also stop the protection of the joints.)

Second, the MRI remission is the medication working, not the disease gone. “La resonancia magnética mostró que no hay inflamación aguda porque el secukinumab está bloqueando la señal inflamatoria. La enfermedad sigue siendo la misma. El daño estructural tiene su propio mecanismo que continúa independientemente. Parar el medicamento permite que la inflamación regrese y que ese proceso se acelere.” (The MRI showed no acute inflammation because secukinumab is blocking the inflammatory signal. The disease is still the same. Structural damage has its own mechanism that continues independently. Stopping the medication allows inflammation to return and that process to accelerate.)

Third, structural damage is silent until it is irreversible. “Las erosiones óseas y el endurecimiento articular en la psoriasis articular no siempre producen dolor suficiente como para que usted note que están pasando. La radiografía anual es la única forma de detectar el daño antes de que sea permanente. Una vez establecido, el daño no se revierte.” (Bone erosions and joint hardening in psoriatic arthritis do not always produce enough pain for you to notice they are happening. The annual x-ray is the only way to detect damage before it is permanent. Once established, damage does not reverse.)

Fourth, methotrexate at rheumatology doses is not cancer chemotherapy. “El metotrexato para artritis inflamatoria y el metotrexato para cáncer tienen el mismo nombre pero dosis completamente diferentes. La dosis de artritis es diez a cien veces menor. Los datos de seguridad a largo plazo no muestran aumento de riesgo de cáncer a esta dosis.” (Methotrexate for inflammatory arthritis and methotrexate for cancer have the same name but completely different doses. The arthritis dose is ten to one hundred times lower. Long-term safety data do not show increased cancer risk at this dose.)

Fifth, feeling well on treatment is evidence that treatment is working — not evidence that treatment can stop. “Sentirse bien es la señal de que el medicamento está funcionando. No es la señal de que la enfermedad desapareció. La enfermedad que usted tiene es crónica — el sistema inmune sigue teniendo la misma programación de base. El medicamento la controla. Sin el medicamento, el control desaparece.” (Feeling well is the sign that the medication is working. It is not the sign that the disease has gone away. The disease you have is chronic — the immune system continues to have the same underlying programming. The medication controls it. Without the medication, the control disappears.)

Psoriatic arthritis is one of the inflammatory arthritides with the greatest gap between visible disease activity and underlying structural progression. The skin is prominent, colorful, and visible; the DIP joint erosion is invisible on daily self-examination and barely painful until advanced; the sacroiliac joint sclerosis is asymptomatic as it forms. The psoriatic arthritis clinic nurse who can explain this gap — in Spanish, with mechanistic specificity, for the patient who stopped methotrexate because the skin looked clear and the joints felt fine — keeps that patient in the treatment window before erosions, before fusion, before the irreversible.

“La piel limpia y las articulaciones sin dolor son señales de que el medicamento está haciendo su trabajo. Son la razón para continuar el medicamento — no la razón para pararlo.”

(Clear skin and painless joints are signs that the medication is doing its job. They are the reason to continue the medication — not the reason to stop it.)

That is the sentence every psoriatic arthritis clinic nurse should be able to say, clearly and from understanding, in the language their patient speaks.

Internal links: Spanish for rheumatology clinic nurses · Spanish for gout clinic nurses · Spanish for ANCA vasculitis clinic nurses · Spanish for SLE neuropsychiatric and pulmonary manifestations clinic nurses